All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub

Brought to you by Scientific Education Support

Scientific Education Support

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My GvHD Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View GvHD content recommended for you

EBMT 2023

Share:

Apr 23, 2023

X post image

26 May 2023

#EBMT23 | 🎥 The GvHD Hub was pleased to speak to @abazarbachi, Jacobi Medical Centre, New York, US.
We asked, Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?

#GvHD
https://t.co/7LvNWPXyS3

X post image

19 May 2023

#EBMT23 | 🎥 The GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE.
We asked, What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?

#gvhd
https://t.co/eQrNZYoEVc

X post image

1 May 2023

Did you miss our live coverage of #EBMT23?

Click here to view our event coverage and catch up on all the major developments 👇

https://t.co/s8nTU2aOUr

#gvhd #bmtsm

X post image

27 Apr 2023

CONGRESS|#EBMT23
Sung Won Choi @UMich presents phase 1/2 results of #Vorinostat in children & adolescent/young adults for #GvHD prophylaxis. Grade 2-4 aGvHD incidence was 11%. Vorinostat was well tolerated & may limit posttransplant cognitive difficulties
#bmtsm #medicalcongress

X post image

27 Apr 2023

CONGRESS|#EBMT23
@QueraltSalas @hematoclinicbcn presents efficacy of PTCy based GvHD-prophylaxis in pts ≥55 yrs with #AML in CR or #MDS undergoing 1st RIC allo-HCT. MUD, MMUD & haplo-HCT groups showed comparable #GvHD incidences than other prophylaxis without PTCy.
#EBMT #bmtsm

X post image

27 Apr 2023

CONGRESS|#EBMT23
Mario Arpinati, #IRCCS Universitaria di Bologna presents results of NCT02749084 evaluating pts with SR cGvHD treated with purified cryopreserved donor T regs. No infusion related events or aGvHD or early flares of cGvHD observed.
#GvHD #medicalcongress #bmtsm

X post image

27 Apr 2023

Congress|#EBMT23
Ehud Even-Or @HebrewU presents age-related survival differences with #etanercept for Grade III-IV SR aGvHD. Children treated with ET had OS of 77.42% vs 38.89% in control group, whereas adults treated with ET died within a year.
#GvHD #bmtsm #medicalcongress

X post image

27 Apr 2023

Congress|#EBMT23
Verena Wais, University Hospital of Ulm presents real-world benefit of ruxolitinib+ECP combination in SR-a/cGvHD. Ruxo+ECP showed ORR of 64% in pts with SR aGvHD and 69% in pts with SR cGvHD. Combination was well tolerated.
#GvHD #bmtsm #medicalcongress

X post image

26 Apr 2023

CONGRESS | #EBMT23
Esteban Arrieta Bolaños, @IztfE talks about alloreactive memory CD4+ T cells that efficiently recognize HLA-DP non-permissive mismatches presenting divergent immunopeptidomes.
#GvHD #bmtsm #medicalcongress

X post image

26 Apr 2023

CONGRESS|#EBMT23
Katia Beider @sheba_medical talks about ex vivo generated ATG-exposed exosomes that contribute to immune modulation in ASCT by upregulating PD-L1 levels, inducing Treg & M2 macrophage subsets, & suppressing T cell proliferation & activation
#GvHD #medicalcongress

X post image

26 Apr 2023

CONGRESS|#EBMT23
@giorgio_orofino @SanRaffaeleMI presents dynamics of immune-reconstitution after #HSCT in pts receiving #letermovir.
Significant reduction of cGvHD and clinically relevant CMV events & CMV disease in LTV-recipients were observed.
#GvHD #bmtsm #medicalcongress

X post image

26 Apr 2023

CONGRESS|#EBMT23
@nivallet, @Inserm talks about high relapse associated with #azithromycin after allo-HSCT. Study in blood samples from pts in ALLOZITHRO trial revealed that AZM blocks T cells signaling & energy metabolism, thereby inhibits antitumor immune responses.
#bmtsm

X post image

26 Apr 2023

CONGRESS|#EBMT23
Emmanuelle Godefroy @Inserm presents how CD73+ DP8αTregs prevents #GVHD. CD73 on DP8αTregs is decreased in aGvHD pts. Mice injected with DP8αTregs maintained weight & colon crypt height, had increased survival, & lower CD4+ T cell infiltration in colon #bmtsm

X post image

26 Apr 2023

CONGRESS|#EBMT23
Zixuan Zhang @HokkaidoUni presents how #Mocravimod ameliorates cGvHD in mice by significantly reducing CD4+ donor T-cells in lymphoid & #GvHD target organs while sparing CD8+ T cells in spleen, bone marrow & liver, thereby maintaining GVL effects.
#bmtsm

X post image

26 Apr 2023

CONGRESS | #EBMT23
Kristina Maas-Bauer, Medical Center @UniFreiburg presents role of ROCK 1/2 inhibition in pathophysiology of #aGvHD. ROCK 1/2 inhibition alters #NFkB signaling and cytokine profile of MPs & DCs and thereby ameliorates #GvHD in mice. #bmtsm #medicalcongress

X post image

26 Apr 2023

CONGRESS | #EBMT23
Jonathan Visentin, @DukeU presents role of DNA-sensor AIM2 in cGvHD pathology. AIM2 promotes IgG-producing B cells and circulating GL7+ B cells in cGVHD mice.
@NIH #GvHD #bmtsm #medicalcongress

X post image

26 Apr 2023

CONGRESS #EBMT23 | @Florent_Malard @Sorbonne_Univ_ speaks about pooled microbiota therapy Maat013 in pts with SR-aGvHD. N=81. GI-ORR at D28=56%: 30 CR, 11 VGPR, 4 PR. ORR (n=78) =49% & inversely correlated with initial aGvHD grade. OS = 51% at 6 mo & 39% at 12 mos. #bmtsm #GvHD

X post image

26 Apr 2023

CONGRESS #EBMT23 | Leslie Kean @DanaFarber discusses survival outcomes 1 yr post allo-HCT in pts given Aba+CNI/MTX vs ATG or PTCy. Aba+CNI/MTX significantly improved 1-yr survival outcomes vs ATG+CNI/MTX. Survival outcomes in 7/8s receiving aba+CNI/MTX ≈ 8/8s. #bmtsm #GvHD

X post image

26 Apr 2023

CONGRESS #EBMT23 | Thomas Luft @uniklinik_hd describes adding MTX vs MMF to GvHD prophylaxis after allo-HCT. N=13,699. Compared to MMF, MTX-complemented CNI prophylaxis was associated with favorable early OS & NRM, & with favorable OS after aGVHD. #bmtsm #GvHD

X post image

26 Apr 2023

CONGRESS #EBMT23 | Kirk R. Schultz @BCChildrensHosp discusses evaluating operational tolerance using machine learning & the ABLE pediatric cohort N=241. 3 subgroups were found. A- Naïve T cell predominant. B - metabolome predominant pattern. C - high Memory Th & Tc #bmtsm #GvHD

X post image

26 Apr 2023

CONGRESS #EBMT23 | Marie Thérèse Rubio, @CHRU_de_Nancy speaks about the influence of systemic complement activation on allo-HCT outcomes. N=85. CA was associated with increased NRM, poor OS & PFS, & increased incidence of gr II–IV aGvHD, & correlated with GI GvHD #bmtsm #GvHDsm

X post image

26 Apr 2023

CONGRESS #EBMT23 | @DrZackDeFilipp @MGHCancerCenter discusses the use of fecal microbiota transplantation to treat HR treatment-naïve lower GI GvHD. N=10. 2 cases of bacteremia, both unrelated to FMT were recorded. At day 28, the ORR was 80% (60% CR, 20% PR). #bmtsm #GvHDsm

X post image

26 Apr 2023

CONGRESS #EBMT23 | @abazarbachi @NYCHealthSystem describes the use of PTCy vs ATG vs PTCy+ATG. N=3,649. Vs PTCy alone, ATG alone had higher risk of NRM (HR=1.55, p=0.004), worse LFS (HR=1.35, p=0.005), OS (HR=1.46, p=0.001), & GVHD-free & GRFS (HR=1.25, p=0.025) #bmtsm #GvHD

X post image

26 Apr 2023

CONGRESS #EBMT23 | @ProfLocatelli presents the results of the pts with SR-cGvHD who crossed over from BAT in the phase III REACH-3 trial of ruxolitinib. N=69 crossed over. Week 24 ORR after crossover =47.8%. CR =4.3% & PR =43.5% #bmtsm #GvHDsm

X post image

26 Apr 2023

CONGRESS|#EBMT23
Iskra Pusic @WUSTLmed presents real word data on #belumosudil & #ruxolitinib combination in SR cGvHD that led to clinical response in ≈43% of pts & stabilized disease in 50% of pts while also allowing prednisone dose-reduction
#GvHD #bmtsm #medicalcongress

X post image

26 Apr 2023

CONGRESS|#EBMT23
Olaf Penack @ChariteBerlin presents comparison between ECP & #ruxolitinib in SR aGvHD in retrospective analysis by #EMBT #TCWP. ORR (58.3% vs 47.5%) was statistically not different in ECP vs ruxolitinib. No major differences in infections seen.
@MNK #bmtsm #GvHD

X post image

25 Apr 2023

CONGRESS|#EBMT23
Yi-Bin Chen @MassGeneralNews presents NCT04014790 phase 2b results of RGI-2001 added to Tac and MTX/MMF for #aGVHD prevention in myeloablative #HSCT. Day-180 OS was 93.9% and Grade II-IV aGvHD-free survival was 75.5%. Safety profile was acceptable.
#bmtsm #GvHD

X post image

25 Apr 2023

CONGRESS | #EBMT23
Lukas Gaksch, @MedUni_Wien presents infiltration patterns of T cells, ILCs, and TRMs in acute GI #GvHD. Higher ILC3s levels and lower TRMs levels observed in steroid responding cohort compared to steroid refractory and reference cohorts.
#bmtsm #medicalcongress

X post image

25 Apr 2023

Congress | #EBMT23
Hyoung Jin Kang of @snuh_official discusses current treatment of SR #cGvHD in Korea. The talk highlights first and second line treatment with #ruxolitinib and #ibrutinib for pediatric cGvHD.
#GvHD #bmtsm #medicalcongress

X post image

25 Apr 2023

Congress | #EBMT23
Olaf Penack of @ChariteBerlin talks about management of SR #GvHD. #Ruxolitinib is recommended in adults with SR #aGvHD and #cGvHD. #Belumosudil and #Ibrutinib are potential therapeutic options for adults with SR cGvHD.
#bmtsm #medicalcongress

X post image

25 Apr 2023

Congress | #EBMT23
Alexandros Spyridonidis of @upatras discusses the role of #posttransplant cyclophosphamide #GvHD prophylaxis in HLA-matched #HSCT. PTCy+Tac/MMF is favorable versus Tac/MTX and PTCy+CsA is favorable versus CsA/MMF.
#bmtsm #medicalcongress

X post image

25 Apr 2023

CONGRESS #EBMT23 | Gérard Socie @HopSaintLouis talks through his opinions on the 6 principles of therapy in chronic GvHD. #bmtsm #GvHD

X post image

25 Apr 2023

CONGRESS #EBMT23 | @Mohty_EBMT discusses the treatment of patients with steroid refractory chronic GvHD. Rux has demonstrated superior efficacy against BAT but doesn't solve the whole problem. Belumosudil may may be an attractive option in the advanced setting #bmtsm #GvHD

X post image

25 Apr 2023

Congress|#EBMT23
@KrogerNicolaus @UKEHamburg discusses the role of ATG/ATLG in preventing #GvHD. ATG/ATLG should be recommended prior to HLA-identical sibling #HSCT, as well as for posttransplant management, as per consensus-based recommendations of #EBMT.
#bmtsm #medicalcongress

X post image

25 Apr 2023

CONGRESS #EBMT23 | @StevenPavletic @theNCI describes the diagnosis and risk assessment of patients with chronic #GvHD in this educational session. He discusses specific organ manifestations such as lung and liver and also factors that affect prognostication such as frailty #bmtsm

X post image

25 Apr 2023

CONGRESS|#EBMT23 Krzysztof Czyzewski, Nicolaus Copernicus University presents analysis on the safety and efficacy of mesenchymal stromal cells in paediatric patients with SR #GVHD. 53% achieved CR and 20% PR. No adverse events were observed #medicalcongress

X post image

25 Apr 2023

CONGRESS|#EBMT23 Alma Wegener @Rigshospitalet presents real world data on ciclosporin, MMF and sirolimus as prophylaxis in patients undergoing NMA HSCT with an HLA-matched unrelated donor. There was a reduction in incidence of grade II-IV #GVHD and improved 2-year OS

X post image

25 Apr 2023

CONGRESS #EBMT23 | Ronjon Chakraverty @ChakravertyLab describes the treatment of patients with SR acute #GvHD with a look at the biological mechanisms. He states that increasing IS is unlikely to work and the priority is to test regenerative therapies with targeted IS #bmtsm

X post image

25 Apr 2023

CONGRESS #EBMT23 | @zina_peric University Hospital Centre Zagreb speaks about the principles of therapy in acute #GvHD. She walks through SD & SR cases & highlights key points for their care. She also discusses approaches to tissue repair in dysbiosis #bmtsm

X post image

25 Apr 2023

CONGRESS #EBMT23 | John Levine @MountSinaiNYC discusses risk assessment in acute #GvHD in this educational session with a focus on biomarkers. He states that the best #GvHD biomarkers quantify damage to the GI tract (e.g. ST2+Reg3a) the organ most resistant to treatment #bmtsm

X post image

24 Apr 2023

Congress #EBMT23 | @shahrukhhashmi & @BipinSavani discusses on how to prevent the complications of chronic #GvHD. The talk emphasizes on recognizing #chronicGvHD, diagnostic testing, choice of prophylaxis regimen, and cost-effective treatment strategy.
#bmtsm #medicalcongress

X post image

24 Apr 2023

CONGRESS #EBMT23 | James Ferrara @MountSinaiNYC describes the use of a serum biomarker & clinical response 2 weeks after treatment as a composite endpoint. N = 1,138. This combo correctly reclassifies 1/2 of clinical NRs as late responders who have excellent OS. #GvHD #bmtsm

X post image

24 Apr 2023

CONGRESS #EBMT23 | Erik Thiele @TU_Muenchen presents multiomics factor analysis of GI metabolites post allo-HCT. High expression of SCFAs, type I IFN metabolites & 2ndary bile acids in allo-HCT pts were correlated with decreased TRM & #GvHD. SRGvHD could be rescued by FMT #bmtsm

X post image

24 Apr 2023

CONGRESS #EBMT23 | Yngvar Floisand @CanCell_UiO reports on the use of vedolizumab in a phase III trial for gastrointestinal acute #GvHD prophylaxis. N=343. Intestinal aGvHD free survival by day +180 post allo-HSCT for vedolizumab+SOC = 85.5% vs placebo+SOC= 70.9% (p<0.001) #bmtsm

X post image

23 Apr 2023

CONGRESS #EBMT23 | Leo Luznik @HopkinsMedicine presents the keynote lecture on PTCy during the opening ceremony of EBMT23. He talks through the the history of the use of PTCy then addresses the current unknowns and future frontiers #bmtsm #GvHD

X post image

23 Apr 2023

CONGRESS #EBMT23 | We are here live and on site in Paris for the first day of the EBMT meeting. Stay tuned for coverage of the opening ceremony #bmtsm #GvHD

X post image

20 Apr 2023

#EBMT23 | The @gvhd_hub will be virtually attending the 49th Annual Meeting of @TheEBMT.

📍 Location: Paris and online
📅 Date: April 23–26

#gvhd #BMTSM

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2023 European Society for Blood and Marrow Transplantation

Newsletter

Subscribe to get the best content delivered to your inbox